Game changing scientific innovation

We combine independent expertise in drug development with extensive business and scientific experience to navigate the complex pathway from lab to commercialisation. Our desire to drive scientific innovation is founded on a patient-centric vision, a clear business strategy, comprehensive product protection, and strong development partnerships. Our open information policy keeps our partners informed of our achievements while respecting the need for confidentiality.

A clear business strategy

We work hard to identify and develop drug candidates with the potential to satisfy the unmet need for disease modifying therapies. TikoMed AB is an investment/holding company that develops projects through daughter companies. We identify and develop molecules for clinical trial then exit projects through a partnering deal or trade sale to biopharmas capable of progressing the drug candidates to market.

Company information

TikoMed AB is a privately owned company based in Viken, Sweden. It is governed by the Laws of the Kingdom of Sweden and was formed in accordance with the Swedish Company Act in 2002.

MANAGEMENT

Adam Bruce, CEO

Acting CEO and Chairman of the Board and founder of TikoMed. Adam is leading the research and development program for IBSOLVMIR, our infusion drug candidate for improving outcomes in cell therapies currently in clinical development for Islet Cell transplantation.

Lars Bruce, Vice President Neurodegeneration - ILB®

VP and Board Member and founder of TikoMed. Lars is leading the research and development program for ILB®, our drug candidate for neurodegenerative diseases currently in clinical development for Amyotrophic Lateral Sclerosis (ALS).

Florence Lange, Senior Coordinator - ILB®

Senior Coordinator for ILB project with more than 30 years’ experience as a Management- and Executive assistant and the expertise of working in a growing company from early stage to major international presence. Before joining TikoMed, Florence was involved in building up the organization and the administrative structure of an international start-up project.

Sten Kornfält, Project Leader - IBSOLVMIR®

Sten holds a pharmacy degree from Uppsala University and is a certified project manager. Sten has extensive experience in research, pharmaceutical development and the pharmaceutical industry and has most recently worked as project manager in different small biotech companies and clinical CROs.

Mats Reslow, CMC Director

Mats holds a PhD in Biotechnology at Lund University and specializes in the development of biological drugs. Mats has extensive experience in drug development and most recently came from Novo Nordisk, Denmark where he worked for 12 years with research and development. Mats has previously worked at Pharmacia, Ferring, Bioglan and SkyePharma.

Elisabeth Servin, Quality Assurance Manager

Elisabeth has +35 years of experience of working with quality management in development, manufacturing, distribution and clinical trials of medicinal products. She has worked at most of the big pharma companies in Sweden and has also supported companies abroad. Since early 2021 she supports TikoMed from her own registered shareholder's company, running from 2018.

Johan Olsson, Chief Financial Officer

Johan holds a Master Degree of Business Administration from Lund University and specializes in accounting and auditing. Johan has previously worked at Nyström & Partners Revision AB, BJT Consulting AB and Personal Accounting Sweden AB.

Claus Sundgreen, Consultant Chief Medical Officer,

Claus holds a medical degree at the University of Copenhagen and a Diploma of Pharmaceutical Medicine from Karolinska Institutet. Claus operates a consulting company with focus on neurodegeneration. Claus was medical director at Orphazyme responsible for the ALS program.

Claus Bo Svendsen, Executive Advisor

Claus Bo Svendsen holds an MD degree and a PhD in sarcoidosis pathobiology at the University of Copenhagen. He is currently the CEO of Forward Pharma that was previously listed on Nasdaq and which licensed out its intellectual property to Biogen for $1.25 billion. Dr. Svendsen is also a co-founder of the Nasdaq-listed company GH Research and an independent strategic consultant for life science companies. He previously worked in Novo Nordisk, including roles of Global Medical Director for Victoza® (liraglutide) and for Saxenda® in its regulatory and pre-launch phase for weight management, supporting a successful FDA advisory committee meeting and finally FDA and EMA approval. Prior to that he was an analyst with Nordic Biotech Advisors ApS, dealing with due diligence of potential investment opportunities.

SCIENTIFIC ADVISORY BOARD - SAB

Merit Cudkowicz, MD, MSC

Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chairof Neurology at Mass General, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with Amyotrophic Lateral Sclerosis (ALS). Dr. Cudkowicz is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over 145 clinical sites in the United States, Canada, Europe and the Middle East dedicated to performing collaborative clinical trials and research in ALS. She has brought innovations to accelerate the development of treatments for people with ALS rapidly.

Caroline Ingre, MD

Researcher Caroline Ingre is an Associate Professor and Research Group Leader, ALS, at the Department of Clinical Neuroscience at Karolinska Institutet. She is a specialist in neuromuscular disease and have been working with ALS for more than 10 years. Caroline has initiated several collaborations between Universities and University Hospitals in Sweden and hosts the national clinical ALS meeting. She also leads an ALS research group at Karolinska Institute with main interests in epidemiology, risk and prognosis of ALS disease, the development of imaging methods, biomarker studies and psychological influence on ALS.

JS

Jeremy Shefner, MD, PhD

Jeremy Shefner, MD, PhD, is a neurologist in the Gregory W. Fulton ALS & Neuromuscular Disease Center and professor in the Department of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology and he specializes in ALS and neuromuscular disorders. Dr. Shefner’s research focuses on biomarker development and the clinical therapeutics of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS), the largest and most active consortium in the world dedicated to ALS. He directs the NEALS outcomes and clinical monitoring cores and is the principal investigator for two multicenter clinical trials, as well as a biomarker study measuring ALS disease progression. Dr. Shefner received his PhD from the University of Illinois in Urbana-Champaign, and his MD from Northwestern University Medical School in Chicago. He completed his residency training at the Harvard Longwood Neurology Training Program in Boston and completed a fellowship in neuromuscular disease at the Brigham and Women’s Hospital in Boston.

Adrian Chio

Prof Adriano Chiò

Prof Adriano Chiò is a neurologist currently working in Torino, Italy. He is Professor of Neurology and Director of the ALS Center at the University of Torino and the Città della Salute e della Scienza Hospital, Torino, Italy. He is director of the ALS Expert Center in Torino, that aims for optimal diagnostic work-up, care and treatment for patients with ALS and other motor neuron diseases in Piedmont. He leads the Italian ALS Genetic (ITALSGEN) Consortium. Adriano Chiò, whose main areas of research are epidemiology, cognition, neuroimaging, and genetics of ALS, is best known for his research on risk of ALS in soccer players, the phenotypic heterogeneity of ALS and has contributed to the discovering of several ALS genes, including C9ORF72, VCP, MATR3 and KIF5A. He has published over 330 papers in peer-reviewed journals. He was awarded the 2015 Sheila Essay Award, presented by the American Academy of Neurology and ALS Association (USA).

BOARD OF DIRECTORS

Adam Bruce, Chairman of the Board

More than 20 years of experience of leading innovation and project development in Life Sciences. Founder of TikoMed and has since served as CEO, Chairman, Head of Business Development and is presently acting CEO, Chairman of the Board and VP advanced therapy with focus on the IBSOLVMIR project.

Lars Bruce, Board Member

Inventor with commercial innovations in mechanics, metallurgy, and medicine. Founder of SinterCast, Nasdaq Stockholm.

Pete Zorn, Board Member

Pete Zorn is currently President and Chief Legal Officer at Genevant Sciences, Inc. Prio to joining Genevant Scienses, Inc. he was the Chief Corporate Officer and General Counsel of Albireo Pharma. He brings two decades of life sciences experience as a business and legal executive and as a track record of company-building corporate development. He earned an undergraduate degree from Harvard University and holds a law degree from the University of North Carolina at Chapel Hill.

Tara Heitner, Board Member

Tara Heitner, PhD, MBA. has over 15 years of international experience in the biopharmaceutical industry. Her experience includes the development and commercialization of early-stage drug discovery technologies and more. Dr. Heitner earned a PhD in Chemistry from McGill University in Montreal, Canada. She earned an executive MBA from Danish Technical University in 2014.